Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Common Equity (2016 - 2026)

Dexcom has reported Common Equity over the past 17 years, most recently at $3.0 billion for Q1 2026.

  • Quarterly Common Equity rose 30.46% to $3.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Mar 2026, up 30.46% year-over-year, with the annual reading at $2.7 billion for FY2025, 30.6% up from the prior year.
  • Common Equity was $3.0 billion for Q1 2026 at Dexcom, up from $2.7 billion in the prior quarter.
  • Over five years, Common Equity peaked at $3.0 billion in Q1 2026 and troughed at $1.8 billion in Q3 2022.
  • The 5-year median for Common Equity is $2.2 billion (2024), against an average of $2.3 billion.
  • Year-over-year, Common Equity dropped 12.74% in 2024 and then skyrocketed 37.75% in 2025.
  • A 5-year view of Common Equity shows it stood at $2.1 billion in 2022, then decreased by 2.96% to $2.1 billion in 2023, then grew by 1.64% to $2.1 billion in 2024, then surged by 30.6% to $2.7 billion in 2025, then grew by 7.68% to $3.0 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Common Equity are $3.0 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025).